ClinicalTrials.gg
Active, not recruitingNCT05351164Updated Jun 12, 2025Results posted

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

A Phase 2 interventional study of Metreleptin in Lipomatosis, Multiple Symmetrical, sponsored by University of Michigan. Active, not recruiting at 1 site in United States. Open to participants aged Up to 60 Years. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by University of Michigan · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
Up to 60 Years
Sex
All
01

Study summary

Participants (homozygous MFN2 [gene that provides instructions to produce the Mitofusin 2 protein] R707W) will be treated with Metreleptin, and effects on body composition, metabolic parameters and safety will be assessed over a 6 month intervention period. Additional safety will be assessed for 1 more year (up to 1.5 years total) in which adverse event data will be collected.

Read the detailed description

In 2024, the IRB granted an amendment that allowed for continued data collection, including adverse events, up to 5 years per participant.

02

Conditions studied

  • Lipomatosis, Multiple Symmetrical

Keywords

  • Metreleptin
03

In context

Lead sponsor

University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.

Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have the clinical diagnosis of MSL and being followed at University of Michigan (cohort to be studied in this proof-of-concept study is already available at Michigan).
  • Willing and able to tolerate the study procedures.
  • Willing and able to tolerate blood sampling.
  • Having no condition that may impede successful data collection or interfere with testing parameters.
  • \<60 years of age.
  • If female of :

    • Not breastfeeding.
    • Negative pregnancy test (human chorionic gonadotropin, beta subunit) at baseline.
  • Can read, understand and sign approved form, communicate with study physician, and study team, and understand and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Presence of advanced liver disease (abnormal synthetic function, [PT], or albumin) in medical records
  • Evidence of other etiologies of viral hepatitis in medical records
  • Presence of active hematologic, bone marrow or other abnormalities that may increase risk of bleeding in medical records.
  • Presence of infection in medical records.
  • Presence of End-stage renal disease (ESRD), active cancer, or >class 2 congestive heart failure based on medical history and physical examination.
  • Active chronic infection (e.g., known chronic osteomyelitis or Tuberculosis [TB]). May have transient infections but must be free of active infection for two weeks prior to study visits.
  • Unable to ambulate or tolerate trips to the University of Michigan Clinical Research Unit.
  • Coronary artery disease (CAD): history of stent or Coronary artery bypass graft surgery (CABG) with cardiologist confirmed angina.
  • Presence of disease.
  • to metreleptin.
  • General obesity not associated with congenital leptin deficiency.
  • Any other condition that, in our opinion, may impede successful data collection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Patients with MSL

    Drug: Metreleptin

Interventions

  • Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).

06

What researchers measure

Primary outcomes

  1. Change in Truncal Adiposity

    A dual-energy X-ray absorptiometry (DEXA) scan was used to measure truncal adiposity at baseline and week 24. Truncal adiposity is the amount of fat a person has in the trunk area, and this outcome measure looked at the change in the fat in this area of the body in relation to the total fat in the participant's body. Results represent the change in the percentage of fat tissue from the trunk area to the total body.

    Time frame: Baseline, Week 24

  2. Change in Total Adiposity

    A dual-energy X-ray absorptiometry (DEXA) scan was used to measure total adiposity at baseline and week 24. Total adiposity is the amount of fat participants had in the body compared to their total weight. Results represent the change in the percentage of fat tissue from the total body to the total weight.

    Time frame: Baseline, Week 24

07

Results

Posted Jun 12, 2025

Participant flow

Participant flow — Overall Study
MilestonePatients With MSL
Started4
Completed4
Not completed0

Outcome measures

PrimaryChange in Truncal Adiposity

A dual-energy X-ray absorptiometry (DEXA) scan was used to measure truncal adiposity at baseline and week 24. Truncal adiposity is the amount of fat a person has in the trunk area, and this outcome measure looked at the change in the fat in this area of the body in relation to the total fat in the participant's body. Results represent the change in the percentage of fat tissue from the trunk area to the total body.

Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of truncal body fat
Change in Truncal Adiposity
percentage of truncal body fatPatients With MSL
Baseline22.8 ± 3.2
Week 2416.0 ± 6.0
Statistical analysis
  • Patients With MSL · t-test, 2 sided · p = 0.004
PrimaryChange in Total Adiposity

A dual-energy X-ray absorptiometry (DEXA) scan was used to measure total adiposity at baseline and week 24. Total adiposity is the amount of fat participants had in the body compared to their total weight. Results represent the change in the percentage of fat tissue from the total body to the total weight.

Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of body weight
Change in Total Adiposity
percentage of body weightPatients With MSL
Baseline21.9 ± 2.3
Week 2416.7 ± 4.7
Statistical analysis
  • Patients With MSL · t-test, 2 sided · p = <0.0001

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With MSL0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPatients With MSL
viral and non-serious bacterial infectionsInfections and infestations3/4
Diarrhea or nauseaGastrointestinal disorders2/4
Musculoskeletal painMusculoskeletal and connective tissue disorders2/4
fall from recreational vehicleInjury, poisoning and procedural complications1/4
weight lossMetabolism and nutrition disorders1/4
planned orthopedic surgerySurgical and medical procedures1/4
palpitations and chest discomfortCardiac disorders1/4
less stamina and strengthGeneral disorders1/4
Hematuria (self resolved)Renal and urinary disorders1/4
high blood pressureBlood and lymphatic system disorders1/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patients With MSL
Mean38.5 ± 19.3
Sex: Female, Male
Sex: Female, Male(Participants)Patients With MSL
Female2
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients With MSL
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients With MSL
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Patients With MSL
United States4
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Apr 2024, 8 months.

Results were first posted in Jun 2025, 1 year 2 months after primary completion. A results delay was requested in Feb 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2022
First posted
Apr 28, 2022
StartActual
Aug 1, 2023
Primary completionActual
Apr 8, 2024
CompletionEst.
Oct 2028
Results delay requested
Feb 14, 2025
Results first posted
Jun 12, 2025
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05351164
Collaborators
Amryt Pharma
Responsible party
Elif Oral (Professor of Internal Medicine, University of Michigan) — Principal investigator
First posted
Apr 28, 2022
Start date
Aug 1, 2023
Primary completion
Apr 8, 2024
Completion
Oct 2028 (estimated)
Results posted
Jun 12, 2025
Last update
Jun 12, 2025

Study contacts

Elif Oral
principal investigator · University of Michigan

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metreleptin

Start the discussion